Agenus receives $25M milestone payment from Bristol Myers Squibb for BMS-986442 trial progress

AGENUS INC

$25M payment received Jan 30, 2024, under global licensing agreement with BMS.
Triggered by dosing of first patient in phase 2 dose expansion of CA115-001 trial of BMS-986442.
This is the second development milestone under the agreement; first achieved previously.
Payment was received on January 30, 2024, as confirmed by the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.